Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Twist Bioscience Corporation (NASDAQ:TWST) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $98.30.

Several equities analysts have commented on the stock. Guggenheim reissued a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Piper Sandler lifted their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. UBS Group set a $89.00 price objective on Twist Bioscience in a research report on Monday, June 15th. Finally, Canaccord Genuity Group raised their target price on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $124.72 on Monday. The firm has a 50-day moving average of $110.90 and a 200-day moving average of $76.90. The company has a market cap of $7.82 billion, a P/E ratio of -56.18 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience has a one year low of $23.30 and a one year high of $155.44.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter last year, the firm posted $0.33 earnings per share. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. Equities research analysts forecast that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 291 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the transaction, the senior vice president directly owned 120,414 shares in the company, valued at $10,514,550.48. The trade was a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 192,697 shares of company stock worth $23,998,505 in the last ninety days. Corporate insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System lifted its holdings in Twist Bioscience by 10,945.7% during the second quarter. California State Teachers Retirement System now owns 7,770,424 shares of the company’s stock valued at $799,421,000 after purchasing an additional 7,700,076 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Twist Bioscience in the second quarter worth about $600,191,000. William Blair Investment Management LLC bought a new stake in shares of Twist Bioscience in the second quarter valued at approximately $223,722,000. EdgePoint Investment Group Inc. raised its position in shares of Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after purchasing an additional 1,295,672 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Twist Bioscience by 151.5% during the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after buying an additional 1,080,722 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.